Korkmaz, E. T. Et Al. 2022. Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?. European annals of allergy and clinical immunology .

Korkmaz, E. T., Aydın, Ö., Mungan, D., Sin, B. A., Demirel, Y. S., & Bavbek, S., (2022). Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?. European annals of allergy and clinical immunology .

Korkmaz, E Et Al. "Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?," European annals of allergy and clinical immunology , 2022

Korkmaz, E T. Et Al. "Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?." European annals of allergy and clinical immunology , 2022

Korkmaz, E. T. Et Al. (2022) . "Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?." European annals of allergy and clinical immunology .

@article{article, author={E T Korkmaz Et Al. }, title={Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?}, journal={European annals of allergy and clinical immunology}, year=2022}